XML 50 R31.htm IDEA: XBRL DOCUMENT v3.25.1
Segments of Business and Geographic Areas (Tables)
 3 Months Ended
Mar. 30, 2025
Segment Reporting [Abstract]  
Sales By Segment Of Business
 Fiscal First Quarter Ended
(Dollars in Millions)March 30,
2025		March 31,
2024		Percent
Change
INNOVATIVE MEDICINE
Oncology
U.S.
$3,0132,38326.4 %
International
2,6642,4309.6 
Worldwide
5,6784,81417.9 
CARVYKTI
U.S.
318140*
International
5116*
Worldwide
369157*
DARZALEX
U.S.
1,8291,46424.9 
International
1,4091,22814.7 
Worldwide
3,2372,69220.3 
ERLEADA
U.S.
2922852.5 
International
47940418.5 
Worldwide
77168911.9 
IMBRUVICA
U.S.
235265(11.5)
International
474518(8.5)
Worldwide
709784(9.5)
RYBREVANT/ LAZCLUZE(1)
U.S.
11336*
International
2811*
Worldwide
14147*
TALVEY(1)
U.S.
68 50 35.2 
International
18 8 *
Worldwide
86 58 48.4 
TECVAYLI
U.S.
1051014.9 
International
463338.8 
Worldwide
15113313.3 
 Fiscal First Quarter Ended
(Dollars in Millions)March 30,
2025		March 31,
2024		Percent
Change
ZYTIGA / abiraterone acetate
U.S.
79(24.3)
International
118172(31.3)
Worldwide
125181(30.9)
OTHER ONCOLOGY
U.S.
473342.9 
International
42414.6 
Worldwide
897321.7 
Immunology
U.S.
2,1962,453(10.5)
International
1,5101,794(15.8)
Worldwide
3,7074,247(12.7)
REMICADE
U.S.
31426618.1 
U.S. Exports
1027(64.2)
International
1431411.3 
Worldwide
4674347.5 
SIMPONI / SIMPONI ARIA
U.S.
29225414.8 
International
36629922.4 
Worldwide
65955418.9 
STELARA
U.S.
9811,396(29.8)
International
6441,055(38.9)
Worldwide
1,6252,451(33.7)
TREMFYA
U.S.
59950917.6 
International
35629919.2 
Worldwide
95680818.2 
OTHER IMMUNOLOGY
U.S.
10*
International
00— 
Worldwide
10*
 Fiscal First Quarter Ended
(Dollars in Millions)March 30,
2025		March 31,
2024		Percent
Change
Neuroscience
U.S.
9681,054(8.1)
International
679749(9.3)
Worldwide
1,6471,803(8.6)
CONCERTA / methylphenidate
U.S.
3841(7.4)
International
110136(18.9)
Worldwide
148177(16.3)
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA
U.S.
625765(18.2)
International
277292(4.9)
Worldwide
9031,056(14.5)
SPRAVATO
U.S.
27619145.0 
International
433425.0 
Worldwide
32022541.9 
OTHER NEUROSCIENCE
U.S.
2858(50.6)
International
248287(13.4)
Worldwide
277345(19.6)
Pulmonary Hypertension
U.S.
744766(2.9)
International
281283(0.6)
Worldwide
1,0251,049(2.3)
OPSUMIT/OPSYNVI(2)
U.S.3633562.1 
International159169(6.0)
Worldwide522524(0.5)
UPTRAVI
U.S.365392(6.9)
International867613.4 
Worldwide 451468(3.6)
OTHER PULMONARY HYPERTENSION(2)
U.S.
1518(12.7)
International3739(4.6)
Worldwide 5256(7.2)
Infectious Diseases
U.S.
315324(2.8)
International
487497(1.9)
Worldwide
802821(2.2)
 Fiscal First Quarter Ended
(Dollars in Millions)March 30,
2025		March 31,
2024		Percent
Change
EDURANT / rilpivirine
U.S.
88(1.3)
International
35031511.0 
Worldwide
35832310.7 
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
U.S.
305314(2.9)
International
98104(6.2)
Worldwide
403418(3.7)
OTHER INFECTIOUS DISEASES(3)
U.S.
227.7 
International
3977(48.8)
Worldwide
4178(47.6)
Cardiovascular / Metabolism / Other
U.S.85563135.4 
International158197(19.7)
Worldwide1,01382922.3 
XARELTO
U.S.69051833.3 
International——— 
Worldwide69051833.3 
OTHER
U.S.16511445.0 
International158197(19.7)
Worldwide3233113.9 
TOTAL INNOVATIVE MEDICINE  
U.S.8,0927,6126.3 
International5,7815,950(2.9)
Worldwide13,87313,5622.3 
MEDTECH
Cardiovascular
U.S.1,2611,02523.0 
International8427817.8 
Worldwide2,1031,80616.4 
ELECTROPHYSIOLOGY
U.S.684692(1.1)
International638652(2.0)
Worldwide1,3231,344(1.6)
ABIOMED
U.S.33930311.9 
International816719.7 
Worldwide42037113.3 
 Fiscal First Quarter Ended
(Dollars in Millions)March 30,
2025		March 31,
2024		Percent
Change
SHOCKWAVE
U.S.206—*
International52—*
Worldwide258—*
OTHER CARDIOVASCULAR
U.S.32307.1 
International726215.1 
Worldwide1039212.5 
Orthopaedics
U.S.1,3841,448(4.4)
International857892(3.9)
Worldwide2,2412,340(4.2)
HIPS
U.S.263270(2.5)
International146152(4.0)
Worldwide409422(3.1)
KNEES
U.S.231242(4.3)
International158160(1.0)
Worldwide389401(3.0)
TRAUMA
U.S.502504(0.5)
International2702613.7 
Worldwide7727650.9 
SPINE, SPORTS & OTHER
U.S.388432(10.2)
International283320(11.6)
Worldwide671752(10.8)
Surgery
U.S.1,0029871.5 
International1,3941,429(2.5)
Worldwide2,3962,416(0.8)
ADVANCED
U.S.4574462.7 
International616641(4.0)
Worldwide1,0731,087(1.2)
GENERAL
U.S.5445420.5 
International778788(1.2)
Worldwide1,3231,330(0.5)
 Fiscal First Quarter Ended
(Dollars in Millions)March 30,
2025		March 31,
2024		Percent
Change
Vision
U.S.5665473.4 
International7137100.4 
Worldwide1,2791,2581.7 
CONTACT LENSES / OTHER
U.S.4524383.1 
International467472(1.1)
Worldwide9199101.0 
SURGICAL
U.S.1141104.3 
International2462383.4 
Worldwide3613483.7 
TOTAL MEDTECH  
U.S.4,2134,0085.1 
International3,8073,813(0.2)
Worldwide8,0207,8212.5 
WORLDWIDE   
U.S.12,30511,6205.9 
International9,5889,763(1.8)
Worldwide$21,89321,3832.4 %
*    Percentage greater than 100% or not meaningful
(1) Previously in Other Oncology
(2) Opsynvi was previously in Other Pulmonary Hypertension
(3) Includes the Covid-19 Vaccine in 2024
Operating Profit by Segment of Business
 Fiscal First Quarter Ended
(Dollars in Millions)March 30,
2025		March 31,
2024
Innovative Medicine(1)
MedTech(2)
Total
Innovative Medicine(1)
MedTech(2)
Total
Sales to customers$13,8738,02013,5627,821
Cost of products sold4,0203,3263,3703,120
Selling, marketing and administrative2,2612,6562,4382,582
Research and development expense2,5486772,896646
Other segment items (3)
(166)(60)(111)(47)
Segment income before tax$5,2101,4216,6314,9691,5206,489
(Income) Expense not allocated to segments (4)
(7,000)2,775
Earnings before provision for taxes on income$13,631$3,714
(1) Innovative Medicine includes:
•Intangible amortization expense of $0.6 billion and $0.7 billion in the fiscal first quarter of 2025 and 2024, respectively.
•A restructuring related charge of $0.1 billion in the fiscal first quarter of 2024. Refer to Note 12 for additional details.
(2)    MedTech includes:
•Intangible amortization expense of $0.5 billion and $0.4 billion in the fiscal first quarter of 2025 and 2024, respectively.
•Acquisition and integration related expense of $0.1 billion in both the fiscal first quarters of 2025 and 2024 primarily driven by the Shockwave acquisition in fiscal 2025 and Abiomed in fiscal 2024.
•A restructuring related charge of $0.1 billion in the fiscal first quarter of 2025.
(3)    Other segment expenses for each reportable segment include charges related to other income and expenses, restructuring activities and impairment charges related to in-process research and development.
(4) Amounts not allocated to segments include interest (income)/expense and general corporate (income)/expense. The fiscal first quarter of 2025 includes the reversal of approximately $7.0 billion, a significant portion of the previously accrued talc reserve. The fiscal first quarter of 2024 includes charges for talc matters of $2.7 billion. For additional details related to talc refer to Note 11 to the Consolidated Financial Statements.

Identifiable Assets
(Dollars in Millions)March 30, 2025December 29, 2024
Innovative Medicine$58,72757,070
MedTech85,11184,322
Total143,838141,392
General corporate (1)
49,83338,712
Worldwide total$193,671180,104
(1)General corporate includes cash, cash equivalents, marketable securities and other corporate assets.
Additions to Property,
Plant & Equipment		Depreciation and
Amortization
(Dollars in Millions)March 30, 2025March 31, 2024March 30, 2025March 31, 2024
Innovative Medicine$276232$8841,011
MedTech480493836746
Segments total7567251,7201,757
General corporate39825258
Worldwide total$795807$1,7721,815
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas
Sales by geographic area
 Fiscal First Quarter Ended
(Dollars in Millions)March 30, 2025March 31, 2024Percent
Change
United States$12,30511,6205.9 %
Europe5,1105,163(1.0)
Western Hemisphere, excluding U.S.1,1671,194(2.3)
Asia-Pacific, Africa3,3113,406(2.8)
Total$21,89321,3832.4 %